| Literature DB >> 31013732 |
Chieh-Jen Wu1,2, Hsin-Hung Chen3,4, Pei-Wen Cheng5,6, Wen-Hsien Lu7,8, Ching-Jiunn Tseng9,10, Chi-Cheng Lai11,12.
Abstract
Studies are extremely limited for the investigation of the clinical outcome of da Vinci robot-assisted bilateral internal mammary artery (BIMA) grafting in coronary artery bypass grafting (CABG) surgery. This study aimed to explore the short-term outcome of da Vinci robot-assisted BIMA grafting through the left pleural space. Relevant data were collected from patients with multi-vessel coronary artery disease receiving two kinds of CABG: a group of patients receiving da Vinci robot-assisted CABG with BIMA grafting, and another group of patients receiving sternotomy CABG with BIMA grafting. Primary endpoints, which included cardiovascular and renal endpoints, were analyzed between the groups using the chi-square test, analysis of variance test, and Kaplan-Meier analysis. Compared with the conventional group (n = 22), the robotic group (n = 22) had a significantly longer operation time (12.7 ± 1.7 vs. 8.5 ± 1.5 hours; p < 0.01) and a marginally lower mean of serum creatinine at baseline (1.2 ± 0.3 vs. 2.0 ± 1.7 mg/dL; p = 0.04). Primary endpoints (5, 22.7% vs. 12, 54.5%; p = 0.03) and renal endpoints (1, 4.5% vs. 7, 31.8%; p = 0.02) at six months were significantly reduced in the robotic group compared with the conventional group. There were no differences in cardiovascular endpoints at six months between the groups (1, 4.5% vs. 0; p = 1.00). The data showed that da Vinci robot-assisted BIMA grafting was safe, with equal cardiovascular events and lowered renal events at six months, as compared to conventional sternotomy BIMA grafting, despite the longer procedure time. The short-term study suggests that da Vinci robot-assisted BIMA grafting may be considered a favorable surgical option for patients with severe coronary artery disease.Entities:
Keywords: bilateral internal mammary artery; coronary artery bypass grafting; coronary artery disease; da Vinci; outcome; sternotomy
Year: 2019 PMID: 31013732 PMCID: PMC6518122 DOI: 10.3390/jcm8040502
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1The patient flow chart. LM = left main; CABG = coronary artery bypass grafting; CAD = coronary artery disease; PCI = percutaneous coronary intervention; LIMA = left internal mammary artery; RIMA = right internal mammary artery; STEMI = ST-segment elevation myocardial infarction; BIMA = bilateral internal mammary artery.
Figure 2Wound healing in robotic and conventional sternotomy-assisted bilateral internal mammary artery grafting via the left pleura in coronary artery bypass grafting surgery. (A) Endoscopy shows that the left internal mammary artery (LIMA) (upper) and the right internal mammary artery (RIMA) (lower) were mobilized using the da Vinci operator system. (B) Surgical wounds (white arrows) of da Vinci robot-assisted CABG are small. (C) Finished anastomoses of LIMA (right) and RIMA (left) with coronary arteries are displayed in an explored sternal area of a sternotomy CABG. (D) A long mid-sternal wound scar (white arrow) is shown in a patient who had received a sternotomy CABG.
Baseline characteristics between two surgical modalities.
| Da Vinci Robotic Surgery | Sternotomy Surgery | ||
|---|---|---|---|
| Male | 20 (90.9) | 21 (95.5) | 1.00 |
| Age (years) | 61.2 ± 12.0 | 62.9 ± 10.5 | 0.63 |
| Body mass index (kg/m2) | 26.9 ± 4.0 | 27.3 ± 3.2 | 0.70 |
| Risk factors for CAD | |||
| Diabetes mellitus | 11 (50.0) | 10 (45.5) | 1.00 |
| Hypertension | 17 (77.3) | 18 (81.8) | 1.00 |
| Dyslipidemia | 13 (59.1) | 12 (54.5) | 1.00 |
| Hyperuricemia | 1 (4.5) | 0 (0) | 1.00 |
| Drug allergy | 5 (22.7) | 1 (4.5) | 0.19 |
| Alcohol drinking | 6 (23.7) | 1 (4.5) | 0.95 |
| Cigarette smoking | 10 (45.5) | 11 (50.0) | 1.00 |
| Family history of CVD | 8 (36.4) | 2 (9.1) | 0.03 |
| CAD condition | |||
| LM | 10 (45.5) | 13 (59.1) | 0.55 |
| TVD | 17 (77.3) | 20 (90.9) | 0.41 |
| DVD | 5 (22.7) | 2 (9.1) | 0.41 |
| Grafting conduit | |||
| BIMA | 22 (100.0) | 22 (100.0) | 1.00 |
| Radial artery | 19 (86.4) | 19 (86.4) | 1.00 |
| GSV | 3 (13.6) | 3 (13.6) | 1.00 |
| Anastomosis number | 3.0 ± 0.6 | 3.4 ± 0.7 | 0.34 |
| On pump | 10 (45.5) | 16 (72.7) | 0.12 |
| On pump time (min) | 123.9 ± 96.2 | 131.4 ± 59.8 | 0.81 |
| Operation room time (h) | 12.7 ± 1.7 | 8.5 ± 1.5 | <0.01 |
| Biomarkers at admission | |||
| Hemoglobin (g/dL) | 13.7 ± 1.6 | 12.7 ± 2.4 | 0.11 |
| Creatinine (mg/dL) | 1.2 ± 0.3 | 2.0 ± 1.7 | 0.04 |
| eGFR (mL/min/1.73 m2) | 65.4 ± 13.6 | 57.9 ± 31.5 | 0.32 |
| CKD stage | 0.11 | ||
| I/II | 15 (68.2) | 10 (45.5) | |
| III | 7 (31.8) | 7 (31.8) | |
| IV | 0 (0) | 3 (13.6) | |
| V | 0 (0) | 2 (9.1) |
Continuous data are presented as mean ± standard deviation; category data are presented as number (percentage); CABG = coronary artery bypass grafting; BMI = body mass index; CAD = coronary artery disease; CVD = cardiovascular disease; LM = left main; TVD = triple vessel disease; DVD = double vessel disease; LIMA = left internal mammary artery; RIMA = right internal mammary artery; eGFR = estimated glomerular filtration rate; CKD = chronic kidney disease.
Adverse events in hospital between two surgical modalities.
| Da Vinci Robotic Surgery | Sternotomy Surgery | ||
|---|---|---|---|
| Hospital stay (days) | 21.0 ± 8.8 | 24.4 ± 14.0 | 0.34 |
| ICU stay (days) | 4.8 ± 3.5 | 5.0 ± 3.3 | 0.90 |
| Ventilator weaning (days) | 2.2 ± 1.8 | 2.3 ± 2.3 | 0.94 |
| Renal events | |||
| CKD stages IV/V | 1 (4.5) | 10 (22.7) | <0.01 |
| Creatinine change >0.5 mg/dL | 5 (22.7) | 7 (31.8) | 0.50 |
| Doubling creatinine (mg/dL) | 1 (4.8) | 3 (13.6) | 0.61 |
| eGFR (mL/min/1.73 m2) * | 58.5 ± 22.1 | 45.5 ± 31.6 | 0.12 |
| Hemodialysis | 0 (0) | 1 (4.5) | 1.00 |
| The lowest hemoglobin (g/dL) | 11.9 ± 1.5 | 12.1 ± 1.5 | 0.57 |
| Blood transfusion (U) | |||
| FFP | 5.3 ± 3.8 | 3.8 ± 4.3 | 0.28 |
| PRBC | 2.1 ± 2.0 | 1.4 ± 2.2 | 0.30 |
| Adverse events | 4 (18.2) | 5 (27.8) | 0.70 |
| Death | 0 (0) | 0 (0) | 1.00 |
| Myocardial infarction | 0 (0) | 0 (0) | 1.00 |
| Stroke | 0 (0) | 0 (0) | 1.00 |
| Wound infection | 1 (4.5) | 1 (5.6) | 1.00 |
| Pneumonia | 1 (4.5) | 0 (0) | 1.00 |
| Pleural effusion | 1 (4.5) | 2 (11.1) | 1.00 |
| Post-operation IABP | 2 (9.1) | 3 (13.6) | 1.00 |
Continuous data are presented as mean ± standard deviation; category data are presented as number (percentage); CABG = coronary artery bypass grafting; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; FFP = fresh frozen plasma; PRBC = packed red blood cells; ICU = intensive care unit; eGFR * = indicate the lowest value of eGFR in hospital; IABP = intra-aortic balloon pump.
Clinical outcomes at six months between two surgical modalities.
| Da Vinci Robotic Surgery | Sternotomy Surgery | ||
|---|---|---|---|
| Finished six months follow-up | 19 (86.5) | 21 (95.5) | |
| Primary endpoints | 5 (22.7) | 12 (54.5) | 0.03 |
| Cardiovascular events | 1 (4.5) | 0 (0) | 1.00 |
| Mortality | 0 (0) | 0 (0) | 1.00 |
| Myocardial infarction | 1 (4.5) | 0 (0) | 1.00 |
| Stoke | 0 (0) | 0 (0) | 1.00 |
| Renal events | 1 (4.5) | 7 (31.8) | 0.02 |
| CKD stages IV/V | 0 (0) | 7 (31.8) | 0.02 |
| Creatinine doubling | 0 (0) | 1 (4.5) | 1.00 |
| Creatinine change >0.5 mg/dL | 1 (4.5) | 5 (22.7) | 0.18 |
| Hemodialysis | 0 (0) | 1 (4.5) | 1.00 |
| eGFR (mL/min/1.73 m2) | 72.1 ± 19.0 | 56.9 ± 34.0 | 0.08 |
| Re-hospitalization * | 4 (18.2) | 6 (27.3) | 0.47 |
Continuous data are presented as mean ± standard deviation; category data are presented as number (percentage); CABG = coronary artery bypass grafting; * = re-hospitalizations due to any cause; primary endpoint = all-cause mortality, myocardial infarction, stock, CKD stages IV/V, and creatinine change >0.5 mg/dL.
Figure 3Kaplan–Meier survival analysis shows a significant reduction in the cumulative incidence of the composite of cardiovascular and renal endpoints at six months (p = 0.03 by log-rank test), including all-cause mortality, non-fatal myocardial infarction, repeated revascularization, non-fatal stroke, the presence of chronic kidney disease stage 4 or 5, creatinine doubling, and a raise of the baseline creatinine >0.5 mg/dL in patients receiving da Vinci CABG as compared with those receiving conventional CABG. CABG = coronary artery bypass grafting.